Literature DB >> 30349944

No alteration of voriconazole concentration by plasmapheresis in a critically ill patient.

Manuela Vay1, Kathrin I Foerster1, Mazyar Mahmoudi1, Jessica Seeßle2, Gerd Mikus3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30349944     DOI： 10.1007/s00228-018-2582-6

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  8 in total

Review 1.  Extracorporeal removal of antimicrobials during plasmapheresis.

Authors:  Polly E Kintzel; Ted Eastlund; Karim Anton Calis
Journal:  J Clin Apher       Date:  2003       Impact factor: 2.821

Review 2.  Drug removal by plasmapheresis: an evidence-based review.

Authors:  Rami B Ibrahim; Chin Liu; Simon M Cronin; Bridgette C Murphy; Raymond Cha; Paul Swerdlow; David J Edwards
Journal:  Pharmacotherapy       Date:  2007-11       Impact factor: 4.705

Review 3.  Pharmacokinetic/pharmacodynamic profile of voriconazole.

Authors:  Ursula Theuretzbacher; Franziska Ihle; Hartmut Derendorf
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

4.  Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections.

Authors:  Andres Pascual; Chantal Csajka; Thierry Buclin; Saskia Bolay; Jacques Bille; Thierry Calandra; Oscar Marchetti
Journal:  Clin Infect Dis       Date:  2012-05-18       Impact factor: 9.079

5.  Pharmacokinetic profile of voriconazole in a critically ill patient on therapeutic plasma exchange.

Authors:  Isabel Spriet; Roger J M Brüggemann; Pieter Annaert; Philippe Meersseman; Eric Van Wijngaerden; Katrien Lagrou; Ludo Willems
Journal:  Ther Drug Monit       Date:  2013-02       Impact factor: 3.681

6.  Protein-binding characteristics of voriconazole determined by high-throughput equilibrium dialysis.

Authors:  Kim Vanstraelen; Joost Wauters; Henriette De Loor; Ine Vercammen; Pieter Annaert; Katrien Lagrou; Isabel Spriet
Journal:  J Pharm Sci       Date:  2014-06-24       Impact factor: 3.534

7.  Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.

Authors:  Thomas F Patterson; George R Thompson; David W Denning; Jay A Fishman; Susan Hadley; Raoul Herbrecht; Dimitrios P Kontoyiannis; Kieren A Marr; Vicki A Morrison; M Hong Nguyen; Brahm H Segal; William J Steinbach; David A Stevens; Thomas J Walsh; John R Wingard; Jo-Anne H Young; John E Bennett
Journal:  Clin Infect Dis       Date:  2016-06-29       Impact factor: 9.079

Review 8.  How to manage aspergillosis in non-neutropenic intensive care unit patients.

Authors:  Matteo Bassetti; Elda Righi; Gennaro De Pascale; Raffaele De Gaudio; Antonino Giarratano; Tereesita Mazzei; Giulia Morace; Nicola Petrosillo; Stefania Stefani; Massimo Antonelli
Journal:  Crit Care       Date:  2014-07-25       Impact factor: 9.097
  8 in total
  1 in total

Review 1.  Drug Dosing in Patients Undergoing Therapeutic Plasma Exchange.

Authors:  Sherif Hanafy Mahmoud; Jessica Buhler; Eric Chu; Suzie A Chen; Theresa Human
Journal:  Neurocrit Care       Date:  2021-02       Impact factor: 3.210
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.